Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort-Reference-Cited by-同舟云学术

Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort

Published:2021-08 Issue: Volume:225 Page:108764
ISSN:0376-8716
Container-title:Drug and Alcohol Dependence
language:en
Short-container-title:Drug and Alcohol Dependence

Author:

Morgan Jake R.^ORCID,Walley Alexander Y.^ORCID,Murphy Sean M.,Chatterjee Avik,Hadland Scott E.^ORCID,Barocas Joshua^ORCID,Linas Benjamin P.,Assoumou Sabrina A.^ORCID

Funder

National Institutes of Health

National Institute on Drug Abuse

National Center for Injury Prevention and Control

Publisher

Elsevier BV

Subject

Pharmacology (medical),Psychiatry and Mental health,Pharmacology,Toxicology

Reference47 articles.

1. Estimated Prevalence of Opioid Use Disorder in Massachusetts, 2011-2015: A Capture-Recapture Analysis;Barocas;Am J Public Health,2018

2. Overdose Deaths Involving Fentanyl and Fentanyl Analogs - New York City, 2000-2017;Colon-Berezin;MMWR Morb Mortal Wkly Rep,2019

3. Opioid use disorder in the United States: Diagnosed prevalence by payer, age, sex, and state;Davenport,2018